Why do so many Alzheimer’s trials fail to deliver actionable insights?

Despite scientific advances, many Alzheimer’s trials continue to face issues with data reliability, patient selection, biological variability, and operational complexity, often limiting their ability to produce clear, reproducible insights.

Watch the webinar where Wemedoo and mediri brought together clinical, imaging, and data perspectives to explore why Alzheimer’s trials so often fall short and what can be done differently to deliver actionable insights.

What you'll learn:

• How the complex biology of Alzheimer’s disease challenges traditional clinical trial designs
• The impact of late diagnosis and heterogeneous patient populations on trial outcomes
• Variability in imaging and biomarker use across sites and vendors
• Why imaging biomarkers are becoming essential in modern Alzheimer’s research
• The importance of standardization for improving data quality and reproducibility
• How integrated data platforms can reduce operational burden and accelerate meaningful insights

Speakers

Prof. Dr. Matthias Günther - Founder & Chief Executive Officer, mediri
Dr. Nikola Cihoric - Founder & Chief Product Officer, Wemedoo

Moderator:

Valérie Czaya - Chief Operating Officer, Wemedoo